Ovidrel vs Compounded hCG: Which Ovulation Trigger Is Right for You?

What Is Ovidrel and How Does It Differ From Compounded hCG?

Ovidrel (choriogonadotropin alfa) is a recombinant human chorionic gonadotropin produced in Chinese hamster ovary cells and approved by the FDA for ovulation induction and ART. The active molecule is identical in amino acid sequence to the naturally occurring hCG produced by the placenta, but it is manufactured without urinary extraction, which means no batch-to-batch protein contamination and no need for complex purification steps.

Compounded hCG is a different story. Most compounding pharmacies use urinary-derived hCG (extracted from the urine of pregnant women) and reconstitute it to a specified IU concentration. The vials require refrigerated storage, reconstitution with bacteriostatic water, and careful dose drawing, steps that introduce more room for handling error than a prefilled auto-injector.

The Potency Problem With IU vs Micrograms

This is where women and their care teams sometimes talk past each other. Ovidrel is dosed in micrograms (250 mcg), while compounded hCG is dosed in international units (IU). The WHO Second International Standard established that 250 mcg of choriogonadotropin alfa produces a biological effect roughly equivalent to 5,000 to 10,000 IU of urinary hCG, depending on the bioassay used. That range exists because the conversion is bioassay-dependent, not a clean 1:1 arithmetic relationship. Clinicians ordering compounded hCG at 5,000 IU and those ordering at 10,000 IU are making meaningfully different choices, not simply adjusting for units.

Manufacturing Quality and Regulatory Oversight

Ovidrel carries full FDA approval under NDA 21-174. Compounded preparations are regulated under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which does not require the same pre-market efficacy and potency testing. The FDA has flagged outsourcing pharmacy quality issues repeatedly, including sterility failures and sub-potent batches in hormone preparations. This does not mean compounded hCG is unsafe when sourced from a reputable 503B facility, but potency verification falls on the dispensing pharmacy, not the FDA.

How the Two Formulations Perform in Clinical Trials

The central question for most women is simple: does the brand matter for the outcome that counts, a live birth?

The honest answer, supported by the published evidence, is that recombinant and urinary hCG produce statistically comparable pregnancy and live-birth rates in most randomized controlled trials, with the differences showing up in side effects, convenience, and subgroup responses rather than headline efficacy numbers.

The Key Head-to-Head Evidence

The Driscoll et al. 2000 trial published in Fertility and Sterility was the key study submitted for Ovidrel's FDA approval. It enrolled women undergoing controlled ovarian stimulation and compared 250 mcg choriogonadotropin alfa to 5,000 IU urinary hCG. Clinical pregnancy rates per attempt were 30.5% with recombinant hCG and 28.5% with urinary hCG, a difference that did not reach statistical significance. Oocyte yield, fertilization rates, and embryo quality were also similar between arms.

A Cochrane review of recombinant versus urinary hCG triggers covering 18 randomized trials found no statistically significant difference in live birth rate (OR 1.08, 95% CI 0.84 to 1.40). The review did note that recombinant hCG was associated with fewer injection-site reactions, likely because the urinary preparations contain non-hCG proteins that provoke local inflammatory responses.

Injection-Site Reactions: a Real Difference for Many Women

For a woman doing her 10th or 15th injectable cycle, injection-site tolerability is not a minor footnote. The same Cochrane analysis found a statistically significant reduction in moderate and severe local reactions with recombinant hCG. If you have had welts, prolonged bruising, or significant pain at the trigger-shot site with urinary hCG, switching to Ovidrel is a clinically reasonable conversation to have with your provider.

OHSS Risk: Does the Formulation Change Your Odds?

Ovarian hyperstimulation syndrome (OHSS) risk is primarily driven by follicle count and estradiol levels at trigger time, not by the specific hCG formulation. Both recombinant and urinary hCG carry meaningful OHSS risk in high responders. A woman with PCOS producing 15 or more follicles is at elevated OHSS risk regardless of whether she receives Ovidrel 250 mcg or compounded hCG 10,000 IU.

In women with PCOS or a predicted high response, the preferred alternative to any hCG trigger is a GnRH agonist trigger (leuprolide acetate 1-2 mg) in GnRH antagonist cycles. This produces a shorter, more physiologic LH/FSH surge, substantially lower OHSS rates, and is recommended by ASRM for high-risk patients. The trade-off is a lower fresh-cycle pregnancy rate, which is why freeze-all strategies are typically paired with agonist triggers.

Sex-Specific Physiology: How Your Hormonal Status Changes the Picture

Women in Their Reproductive Years Doing IVF or IUI

For most women reading this, the trigger shot is one step in an IVF or IUI cycle that has been carefully timed to your follicle sizes and estradiol level. The trigger works by mimicking the natural LH surge your body produces at ovulation. Because recombinant choriogonadotropin alfa and urinary hCG bind the same LH receptor, they initiate the same downstream cascade: oocyte maturation, cumulus expansion, and follicular rupture approximately 36 to 38 hours post-injection.

Your menstrual cycle history matters when your clinic times the trigger. Women with irregular cycles, including those with PCOS, may have baseline LH elevations that complicate the pre-trigger picture. A premature LH surge before the trigger can compromise the cycle. GnRH antagonist suppression protocols reduce this risk and are increasingly the default in PCOS-related ART cycles.

Women With PCOS

PCOS affects 8 to 13% of women of reproductive age and is the most common cause of anovulatory infertility. In PCOS, the ovaries often produce a large cohort of small antral follicles, which means that both hCG formulations carry elevated OHSS risk. The choice between Ovidrel and compounded hCG is secondary to the larger decision about whether hCG is the right trigger class at all. Many PCOS specialists now default to GnRH agonist triggers with freeze-all protocols, reserving hCG triggers for women with a predicted low or normal response.

Women With Diminished Ovarian Reserve

In poor responders, the conversation shifts. A woman with a low antral follicle count and high FSH has minimal OHSS risk, and the goal is maximizing the biological effect of each trigger. Some reproductive endocrinologists use dual triggering: a GnRH agonist plus a full-dose hCG (either Ovidrel 250 mcg or 10,000 IU urinary hCG) to recruit any remaining follicles into the final maturation window. The evidence for dual triggering in poor responders comes primarily from retrospective data, but a prospective study by Haas et al. found higher mature oocyte yields with dual vs. Agonist-alone trigger in this group.

Perimenopause and Egg Donation Protocols

Ovidrel and compounded hCG are not used for standard ovarian stimulation in postmenopausal women, because there are no follicles to trigger. The exception is egg donation cycles, where the donor (typically a young woman in her reproductive years) receives the trigger and undergoes retrieval, while the recipient, who may be perimenopausal or postmenopausal, prepares her uterus with estrogen and progesterone for the embryo transfer. If you are an egg recipient, the trigger shot conversation belongs to your donor's protocol, not yours.

Pregnancy and Lactation: What You Must Know

hCG is classified as FDA Pregnancy Category X. Both Ovidrel and compounded hCG are contraindicated once pregnancy is confirmed. This is not a pharmacologic safety concern in the traditional sense: endogenous hCG is the first hormone your own placenta produces after implantation. The X classification exists because administering exogenous hCG after pregnancy is established serves no therapeutic purpose, can confound serum beta-hCG monitoring used to confirm viable pregnancy, and the controlled trials that establish safety for any new indication have simply never been done in confirmed pregnancy.

For women using hCG as a trigger in ART cycles, the standard timing means the injection happens days before any possibility of confirmed pregnancy, so this is largely a labeling and monitoring issue rather than a clinical risk you are likely to encounter directly.

Lactation Transfer

There are no adequate studies of choriogonadotropin alfa transfer into human breast milk. HCG is a large glycoprotein (molecular weight approximately 36,000-40,000 Da), and large proteins are generally poorly absorbed from the neonatal gut, which reduces the likelihood of clinically significant infant exposure even if transfer into milk occurs. However, because no lactation pharmacokinetic data exist for recombinant choriogonadotropin alfa specifically, the FDA label advises caution and a risk-benefit discussion with your provider.

Women undergoing fertility treatment while nursing a prior infant should discuss cycle timing and the single-dose nature of the trigger with their reproductive endocrinologist. The one-time subcutaneous injection has a half-life of approximately 29 hours for the initial alpha and beta subunit distribution phase, with a terminal half-life of approximately 24 hours for the beta subunit clearance.

Contraception Requirements

No reliable contraception is required in the traditional teratogen sense, because Ovidrel and compounded hCG are given as a single dose precisely to support conception, not to prevent it. The relevant safety instruction here is the opposite: do not take any additional hCG product after the trigger shot, as serial hCG administration during the luteal phase is not standard care and can confuse pregnancy monitoring. If you are not pursuing pregnancy (rare scenario where hCG is used off-label), use of a reliable contraceptive method during the cycle is advised.

Who This Option Is Right For (and Who Should Consider an Alternative)

Ovidrel Is a Good Fit If:

• You prefer a prefilled, single-use pen that requires no reconstitution
• You have had moderate-to-severe injection-site reactions with urinary-derived hCG
• Your pharmacy and insurance cover it (some plans prefer branded biologics over compounded preparations)
• You are in a clinic that standardizes on recombinant protocols for potency consistency

Compounded hCG Is Reasonable If:

• Cost is a genuine barrier and your clinic uses a reputable 503B outsourcing pharmacy
• Your provider's standard protocol is calibrated to urinary hCG IU dosing based on their own outcome data
• You are in a clinic that closely monitors and verifies potency from their compounding source
• Your insurance reimburses compounded hCG but not branded Ovidrel

Neither Formulation Is the Best First Choice If:

• You have PCOS with a predicted high follicle response (GnRH agonist trigger preferred)
• You have had OHSS in a prior cycle (GnRH agonist trigger preferred, freeze-all protocol)
• You are in an egg donor recipient cycle (your trigger protocol does not apply)
• Your AMH and antral follicle count suggest poor reserve and your team is considering dual trigger (discuss the specific protocol before committing to either formulation alone)

Practical Administration: Doing It Right

Ovidrel Subcutaneous Injection

Ovidrel comes ready to inject from the prefilled syringe. Inject subcutaneously into the lower abdomen, approximately 1-2 inches from the navel, at the time specified by your clinic, which is typically timed to target retrieval exactly 36 hours later. Rotate sites if you have been doing daily stimulation injections in the same area.

Compounded hCG Reconstitution Steps

Compounded hCG arrives as a lyophilized powder vial with a separate bacteriostatic water diluent. Typical reconstitution:

1. Draw the specified volume of bacteriostatic water (commonly 1 mL) into a mixing syringe.
2. Inject slowly into the hCG vial, rolling gently to dissolve. Do not shake.
3. Draw the reconstituted solution into your injection syringe.
4. Inject subcutaneously or intramuscularly per your clinic's instruction. Some protocols use IM injection for the full 10,000 IU dose.
5. Discard any unused portion. Compounded vials are typically single-use.

Reconstituted compounded hCG should be used immediately or refrigerated and used within 24 hours, per your pharmacy's labeling.

The 36-Hour Rule and Why Timing Matters

Your clinic will give you an exact time to inject. Take it seriously. Follicular rupture typically occurs 36 to 38 hours post-hCG trigger, and egg retrieval is scheduled to occur just before rupture. Injecting too early or too late by more than 30 to 60 minutes shifts this window and can result in retrieving post-ovulatory oocytes or, conversely, follicles that have not yet completed maturation. Set two alarms. Have a backup plan if your usual injection partner is unavailable.

Cost, Insurance, and Access in 2025

The list price of Ovidrel 250 mcg is approximately $100 to $150 per prefilled syringe at most U.S. Pharmacies. With manufacturer coupons (Merck's patient assistance programs), out-of-pocket costs can drop to $20 to $50 for eligible commercially insured patients.

Compounded hCG at 5,000 to 10,000 IU from a 503B pharmacy typically costs $30 to $70 per vial, making it the lower-cost option when paying out of pocket. However, some insurance plans that cover fertility medications will reimburse Ovidrel but not compounded preparations, because compounded drugs lack NDC codes that insurance adjudication systems require. Verify your specific benefit before your clinic submits the prescription.

Pharmacy availability has also periodically been affected by hCG shortages. Between 2019 and 2022, FDA-documented drug shortages disrupted urinary hCG supply for fertility programs nationally. Ovidrel, as a manufactured biologic with a defined supply chain, has been more consistently available during those periods, which is a practical argument for it beyond the potency consistency point.

A Clinical Note on Off-Label hCG Use in Women

HCG is sometimes prescribed off-label for luteal phase support in early pregnancy, weight loss protocols, and even female libido or testosterone support. The evidence for weight loss and libido applications is essentially absent. The evidence base does not support hCG for weight loss, and the FDA and FTC have both acted against products marketed for this purpose. Luteal phase hCG support after ART is a separate, cycle-specific clinical decision made by your reproductive endocrinologist, not a general wellness supplement.

If a provider or online pharmacy is pitching compounded hCG for any of these purposes, that is a materially different context than fertility treatment, and the risk-benefit calculation does not transfer from the ART evidence base.

The Evidence Gap: What We Do Not Know About Women Specifically

The landmark trials comparing recombinant to urinary hCG enrolled predominantly younger women with presumed normal ovarian reserve. Women over 38, women with a single ovary, women with endometriosis-associated poor response, and women with autoimmune conditions affecting the ovary are poorly represented in the published RCTs. The Cochrane review noted heterogeneity across trials in stimulation protocols, luteal support regimens, and embryo transfer timing, making subgroup conclusions uncertain.

For women in these less-studied groups, the clinical decision defaults to your reproductive endocrinologist's practice-level data and your own prior cycle history. What worked in your last cycle, including which trigger formulation, is real-world evidence about your own physiology that matters at least as much as the population average.